These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 32487617)
1. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells. Nakazawa T; Murakami T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Park YS; Motoyama Y; Tsujimura T; Wakabayashi T; Nakase H Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617 [TBL] [Abstract][Full Text] [Related]
2. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells. Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149 [TBL] [Abstract][Full Text] [Related]
3. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H Cells; 2020 Apr; 9(4):. PubMed ID: 32316275 [TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636 [TBL] [Abstract][Full Text] [Related]
5. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma. Kang CH; Kim Y; Lee SM; Choi SU; Park CH Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386 [TBL] [Abstract][Full Text] [Related]
6. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell. Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736 [TBL] [Abstract][Full Text] [Related]
7. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108 [TBL] [Abstract][Full Text] [Related]
8. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245 [TBL] [Abstract][Full Text] [Related]
9. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
11. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Tachi T; Kijima N; Kuroda H; Ikeda S; Murakami K; Nakagawa T; Yaga M; Nakagawa K; Utsugi R; Hirayama R; Okita Y; Kagawa N; Kishima H; Imai C; Hosen N Cancer Immunol Immunother; 2024 Oct; 73(12):256. PubMed ID: 39367952 [TBL] [Abstract][Full Text] [Related]
15. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment. Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794 [TBL] [Abstract][Full Text] [Related]
18. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma. Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A Cancer Gene Ther; 2024 Sep; 31(9):1323-1334. PubMed ID: 38582787 [TBL] [Abstract][Full Text] [Related]
19. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266 [TBL] [Abstract][Full Text] [Related]
20. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Zhu H; You Y; Shen Z; Shi L Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]